Additionally, recent research found EZH2 GoF mutations can attenuate the B cell's requirement for T cell help, drive the expansion of GC centrocytes and initiate FL in mouse model.[8] However, the clinical efficacy of tazemetostat and other PRC2 drugs has been observed in FL and DLBCL patients without EZH2 GoF mutations. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.